Mibefradil
From Wikipedia, the free encyclopedia
 |
|
|
Mibefradil
|
|
| Systematic (IUPAC) name | |
| (1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C29H38FN3O3 |
| Mol. mass | 495.63 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Withdrawn from market |
| Routes | Oral |
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market,[1] due to the potential for drug interactions, some of them serious, which may occur when it is taken together with some other medications.
[edit] References
- ^ Letter from Roche Laboratories: http://www.fda.gov/medwatch/SAFETY/1998/poscor.htm
